CUROCOM Co., Ltd., together with its subsidiaries, develops software solutions for financial institutions in South Korea. It operates through Solution, Product Distribution, and New Drug and Vaccine Development divisions. The company offers bank automation and network control system for Korea (BANCS-K). It also provides IT outsourcing services, including information system development; ERP development and operation; sales system development and operation; vehicle management system development and operation; and operation of website and shopping mall integrated management systems. In addition, the company distributes IT products, such as LED monitors, TV monitors, solid-state drives, computers, laptops, and printers. Further, it engages in the development, production, and sales of infectious disease vaccines, therapeutic vaccines, and vaccines developed for alternative routes of administration. The company develops its products based on its VSV vector technology. Its product pipeline includes SAV001, a product candidate in Phase 1 clinical trials to treat HIV/AIDS; and product candidates in preclinical trials for the treatment of COVID-19, hepatitis C, Ebola virus, MERS virus, Zika virus, and SFTS/HFRS. CUROCOM Co., Ltd. was founded in 1997 and is headquartered in Seoul, South Korea.